HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda
GlobeNewswire
— If approved in the European Union, fruquintinib will be the first novel targeted therapy for metastatic colorectal cancer..